drugset
Drugs / Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
last change Nov 2022 re-read 2 minutes ago

Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)

Vaccine

Developed for
human papilloma virus infection
Investigated by
Beijing Health Guard Biotechnology, Inc · Mile City Center for Disease Control and Prevention · National Institutes for Food and Drug Control, China · Qiubei County Center for Disease Control and Prevention · Shanghai Stem Pharmaceutical Development Co., Ltd. · Yanshan County Center for Disease Control and Prevention
+1 more · Yunnan Center for Disease Control and Prevention

Trials 1 · a red edge is where a trial was stopped

today NCT05662020 · Ph 3
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05662020 Mar → Nov 2022 overdue human papilloma virus infection Beijing Health Guard Biotechnology, Inc Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) ClinicalTrials.gov intervention name — accepted as the source's own label NCT05662020 ↗
Modality Vaccine “Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)” NCT05662020 ↗